SCHEMBL25759699

SCHEMBL25759699

COc1ccc(-c2ccc(S(=O)(=O)NCCCN3CCC(Cc4ccccc4)CC3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.59
HTR2A P28223 3/20 0.58
HTR1A P08908 2/20 0.58
HTR2C P28335 2/20 0.58
HTT P42858 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
SLC6A2 P23975 3/20 0.55
SLC6A4 P31645 3/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 1/20 0.55
CCR3 P51677 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758335 0.97 HTR7 (0.62) HTR7HTR2AHTR1AHTR2CHTT
SCHEMBL24069429 0.91 SLC6A2 (0.63) HTR7HTTSMN1; SMN2MEN1KMT2A
SCHEMBL25758544 0.89 MEN1 (0.69) HTR7HTR2AHTR1AHTTSMN1; SMN2
SCHEMBL25758331 0.88 MEN1 (0.58) HTR7HTR2AHTR1AHTR2CHTT
SCHEMBL25290527 0.88 SLC6A2 (0.59) HTR7HTR1AHTTSMN1; SMN2MEN1
SCHEMBL25758526 0.87 CCR3 (0.58) HTR7HTR1AHTTSMN1; SMN2MEN1
SCHEMBL25758537 0.87 HTR7 (0.58) HTR7HTTSMN1; SMN2MEN1KMT2A
SCHEMBL30376178 0.86 HTR7 (0.69) HTR7HTTSMN1; SMN2MEN1KMT2A
SCHEMBL24069402 0.86 TMEM97 (0.60) HTR7HTTSMN1; SMN2MEN1KMT2A
SCHEMBL25758409 0.85 HTR7 (0.58) HTR7HTR2AHTR1AHTR2CHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 HTR7 79/4885HTR2A 20/4885HTR1A 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.